Immunos Therapeutics AG has received full ethical institutional approval from the Human Research Ethics Committee (HREC) and regulatory approval from the Australian Therapeutic Goods Administration (TGA) to conduct a phase I trial of its lead program IOS-1002 in Australia.

MGFB, a subsidiary of Fairwinds Bio, has entered into a patent license agreement with Mayo Clinic to advance experimental cancer vaccine therapeutics based on a novel platform developed at Mayo.